|
Everolimus This page contains brief information about everolimus and a collection of links to more information about the use of this drug, related news and research results, and ongoing clinical trials. | US Brand Name(s): |  | Afinitor | | | | FDA Approved: | | Yes |
Everolimus is approved by the Food and Drug Administration (FDA) to treat patients with advanced renal cell carcinoma who have already been treated with sunitinib or sorafenib and have not gotten better.
Everolimus is also approved to be used in a medical device called a stent to treat coronary (heart) artery disease. The drug is released over time, from the stent into the wall of the coronary artery. This helps to keep the artery open. This use comes under the brand name Xience V.
Everolimus is being studied in the treatment of other types of cancer and other conditions. Information from the FDA
FDA Approval for Everolimus - Information from the FDA about the approval of this drug and the clinical trials that led to the approval.
Information from the NCIDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Clinical Trial Results: Everolimus Extends Progression-Free Survival in Advanced Kidney Cancer (07/30/2008) - Important clinical trial results for this drug, background information, and how the trial was done.
Rapamycin Agent Improves Response to Low-Dose Cisplatin (04/05/2005) - Information about the use of this drug to treat cancer.
Clinical TrialsClinical Trials for Everolimus - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.
Important: The drug information on this Web page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top |
